{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By SABRINA TAVERNISE", "person": [{"firstname": "Sabrina", "rank": 1, "lastname": "TAVERNISE", "organization": "", "role": "reported"}]}, "abstract": "Food and Drug Administration approves eteplirsen, medication for Duchenne muscular dystrophy, overriding objections by their own experts and bowing to intense patient lobbying; vote leads stock of drug maker Sarepta Therapeutics to soar. ", "type_of_material": "News", "word_count": "747", "keywords": [{"rank": "1", "value": "Muscular Dystrophy", "is_major": "Y", "name": "subject"}, {"rank": "2", "value": "Food and Drug Administration", "is_major": "Y", "name": "organizations"}, {"rank": "3", "value": "Sarepta Therapeutics Inc.", "is_major": "Y", "name": "organizations"}, {"rank": "4", "value": "Clinical Trials", "is_major": "N", "name": "subject"}, {"rank": "5", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}], "lead_paragraph": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness.", "pub_date": "2016-09-20T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "The decision went against the recommendation of independent experts, and the agency is requiring an additional trial to confirm effectiveness....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/20/business/20DRUG/20DRUG-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/20/business/20DRUG/20DRUG-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/20/business/fda-approves-muscular-dystrophy-drug-that-patients-lobbied-for.html", "slideshow_credits": null, "blog": [], "_id": "57e05a7b95d0e021d7987280", "headline": {"main": "F.D.A. Approves Muscular Dystrophy Drug That Patients Lobbied For", "print_headline": "F.D.A. Clears Debated Drug That Patients Lobbied For"}}